Turku PET Centre, Turku University Hospital and University of Turku.
Institute of Clinical Medicine, University of Eastern Finland.
J Atheroscler Thromb. 2024 Jul 1;31(7):1058-1071. doi: 10.5551/jat.64623. Epub 2024 Feb 23.
Clinical risk scores for coronary artery disease (CAD) are used in clinical practice to select patients for diagnostic testing and therapy. Several studies have proposed that polygenic risk scores (PRSs) can improve the prediction of CAD, but the scores need to be validated in clinical populations with accurately characterized phenotypes. We assessed the predictive power of the three most promising PRSs for the prediction of coronary atherosclerosis and obstructive CAD.
This study was conducted on 943 symptomatic patients with suspected CAD for whom the phenotype was accurately characterized using anatomic and functional imaging. Previously published genome-wide polygenic scores were generated to compare a genetic model based on PRSs with a model based on clinical data. The test and PRS cohorts were predominantly Caucasian of northern European ancestry.
All three PRSs predicted coronary atherosclerosis and obstructive CAD statistically significantly. The predictive accuracy of the models combining clinical data and different PRSs varied between 0.778 and 0.805 in terms of the area under the receiver operating characteristic (AUROC), being close to the model including only clinical variables (AUROC 0.769). The difference between the clinical model and combined clinical + PRS model was not significant for PRS1 (p=0.627) and PRS3 (p=0.061). Only PRS2 slightly improved the predictive power of the model (p=0.04). The likelihood ratios showed the very weak diagnostic power of all PRSs.
The addition of PRSs to conventional risk factors did not clinically significantly improve the predictive accuracy for either coronary atherosclerosis or obstructive CAD, showing that current PRSs are not justified for routine clinical use in CAD.
临床冠状动脉疾病(CAD)风险评分用于临床实践中选择进行诊断检测和治疗的患者。多项研究提出,多基因风险评分(PRS)可以提高 CAD 的预测能力,但评分需要在具有准确特征表型的临床人群中进行验证。我们评估了三种最有前途的 PRS 对冠状动脉粥样硬化和阻塞性 CAD 预测的预测能力。
这项研究纳入了 943 例疑似 CAD 的有症状患者,使用解剖和功能成像对其表型进行了准确的描述。生成了先前发表的全基因组多基因评分,以比较基于 PRS 的遗传模型和基于临床数据的模型。测试和 PRS 队列主要是北欧裔的白种人。
所有三种 PRS 均在统计学上显著预测冠状动脉粥样硬化和阻塞性 CAD。在接受者操作特征曲线(AUROC)方面,结合临床数据和不同 PRS 的模型的预测准确性在 0.778 到 0.805 之间变化,接近仅包含临床变量的模型(AUROC 0.769)。PRS1(p=0.627)和 PRS3(p=0.061)的临床模型与组合临床+PRS 模型之间的差异不显著。PRS2 仅略微提高了模型的预测能力(p=0.04)。似然比表明所有 PRS 的诊断能力都非常弱。
将 PRS 添加到传统危险因素中并未在临床上显著提高对冠状动脉粥样硬化或阻塞性 CAD 的预测准确性,表明当前的 PRS 没有理由在 CAD 的常规临床使用中得到支持。